Focusing the issues of administrative legal regulation in the field of public health in general and the social relations of the emerging in the field of drug products regulation, the author's approach to the consideration of the problems of «alternative medicine» is revealed, in the healthcare system of the modern state, whose policy is based on scientific knowledge and effective cultivation of highly social behavioral algorithms of the population. From a legal point of view, the article describes the concepts of «alternative medicine» and «alternative drugs» related to it. The analysis some of legal acts, scientific researches of various humanitarian and fundamental directions allowed to reflect the most important directions of the state health policy improvement in the opinion of the authors, which consist in the use of administrative legal means in informing the population and increasing individual medical literacy.
Шевырев Д.Н
Дальневосточный юридический институт МВД России
Publications of the author
In the journalPublished: 15 October 2014
The problem of emergence of the illegal pharmaceutical products is generally recognized and relevant for the all developing countries. In this case, the risk of such products increases in proportion to the total pharmaceutical market.The basic ideas of the quality assurance, good manufacturing practices (GMP), quality control and risk management for the quality are interrelated. Abroad are published a lot of literature on the topic of GMP, which was written by former inspectors of the supervising bodies are published, but in Russian there is a lack of such literature, which complicates understanding. This article provides a brief, general description of the system of GMP (Good Manufacturing Practice) for the pharmaceutical industry, in accordance with the international experience and the current legislation of the Russian Federation. An approach to the definition of unsafe medicines in the United States is discussed. This circumstance is the need to optimize the system of preventing the production and trafficking of counterfeit drugs and topical issues of the terminology used in a potentially dangerous drug, in the Russian Federation.
